There are any number of reasons why cardiac leads may need to be removed, and Spectranetics is committed to providing the tools for safe, predictable lead extraction.”
Colorado Springs, CO (PRWEB) May 02, 2013
May 8 through 11, Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Session, convenes in Denver, bringing together more than 8,000 attendees and the world's most noted experts in cardiac rhythm management. The Spectranetics Corporation (NASDAQ: SPNC), headquartered in Colorado Springs, will have a major presence to showcase their proprietary laser lead extraction technology and training.
Spectranetics was founded in Colorado Springs more than 30 years ago, and today the company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The company’s products are sold in more than 40 countries and are used to access and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads.
A full day of the conference is dedicated to a Lead Management Forum, offering attendees the opportunity to explore practical aspects of lead development, implantation, follow up and extraction.
Conference highlights include:
- Simulated cardiac lead laser extraction procedures in a replicated surgical suite in the exhibit booth. Over the three days of the conference, physicians will train on the equipment in both foundational and advanced scenarios to increase their proficiency in lead extraction techniques.
- Physician speakers and round table in the Spectranetics Booth 1602:
Thursday, May 9, 10:00 a.m. – Steven P. Kutalek, MD, FHRS, CCDS
Associate Professor, Drexler University Hospital and Hahnemann UniversityHospital in Philadelphia
"What to Do When You Can't Advance"
Thursday, May 9, 3:30 p.m. – John A. Andriulli, MD, FACC
Cooper University Hospital, Camden, NJ.
"Considerations for Extracting Sprint Fidelis and Riata Leads"
Friday, May 10, 10:00 a.m. Round Table Discussion led by Dale Yoo, MD
"Starting a Program: Successful Lead Management from the Ground Up"
- On Thursday, May 9, an abstract session – Simulation Training Efficacy to Improve Extraction Performance (STEEP) – will be presented by a team led by Dr. Melanie Matin.
In addition, the First Annual Worldwide Lead Management Collaborative Community Meeting hosted in conjunction with the Cleveland Clinic Heart & Vascular Clinic will take place on Wednesday evening, May 8, immediately preceding the opening of the HRS conference. Lead recalls and infected systems will be highlighted as key topics of interest.
According to Tom Daily, Director of Training, for Spectranetics, the training sessions at the Heart Rhythm Society conference and the year-round training offered by a mobile simulator unit respond to the needs of growing ranks of physicians performing lead extraction. "Over 4.5 million people worldwide have an implanted cardiac device, and 1 million new leads are implanted annually," said Daily. "Since their inception 50 years ago, these devices have improved quality of life and extended the longevity of many patients, often extending beyond the expected lifespan of the device itself. There are any number of reasons why leads may need to be removed, and Spectranetics is committed to providing the tools for safe, predictable lead extraction.”
In the past year, Spectranetics has hosted 19 simulator events and trained 378 physicians. The company expects to double both the number of events and physician trainings in 2013.
The original Laser Lead Extraction Simulator was developed in partnership with Medical Simulation Corporation (MSC) in conjunction with MSC’s SimSuite® simulation technology platform.
Spectranetics invites conference attendees to visit the exhibit in booth 1602.
Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The company’s products are sold in more than 40 countries and are used to access and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads.
The company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee. The company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. In addition, the company markets aspiration and cardiac laser catheters for the treatment of blockages in the heart, and drug delivery catheters for vascular delivery of drugs and diagnostic agents.
The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit http://www.spectranetics.com.
Safe Harbor Statement
This news release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), as amended, and the Private Securities Litigation Reform Act of 1995, and is subject to the safe harbor created by that section. Forward-looking statements contained in this release constitute our expectations or forecasts of future events as of the date this release was issued and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “enable,” “potential,” and other words and terms of similar meaning in connection with any discussion of, among other things, clinical trials, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and product development. You are cautioned not to place undue reliance on these forward-looking statements and to note that they speak only as of the date hereof. Factors that could cause actual results to differ materially from those set forth in the forward-looking statements are set forth in the risk factors listed from time to time in our filings with the SEC. Readers are encouraged to review Item 1A. – Risk Factors and all other disclosures appearing in the Spectranetics Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission, for further information on risks and uncertainties that could affect Spectranetics’ business, financial condition and results of operation. We disclaim any intention or obligation to update or revise any financial projections or forward-looking statements due to new information or other events.
Source: The Spectranetics Corporation